Syndax Pharmaceuticals (STU:1T3) ROCE %: -31.18% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1T3 Syndax Pharmaceuticals Inc STU:1T3
34 GF Score
Price €19.84
GF Value €698.80
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals ROCE %?

Syndax Pharmaceuticals STU:1T3 -3.27% 34 ROCE % is -31.18% as of Mar. 2026. GuruFocus rates STU:1T3 with a GF Score™ of 34/100 and a GF Value™ of €698.80 (Possible Value Trap). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Syndax Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -31.18%.

Syndax Pharmaceuticals  (STU:1T3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Syndax Pharmaceuticals ROCE % Related Terms

Syndax Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals ROCE % Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.77 -33.60 -40.35 -54.39 -45.57

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.73 -48.03 -45.14 -55.23 -31.18
STU:1T3
34GF Score
Syndax Pharmaceuticals Inc STU:1T3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals ROCE % Calculation

Syndax Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-214.898/( ( (692.199 - 98.889) + (452.369 - 102.579) )/ 2 )
=-214.898/( (593.31+349.79)/ 2 )
=-214.898/471.55
=-45.57 %

Syndax Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-106.66/( ( (452.369 - 102.579) + (408.858 - 74.541) )/ 2 )
=-106.66/( ( 349.79 + 334.317 )/ 2 )
=-106.66/342.0535
=-31.18 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -31.18% mean?
Syndax Pharmaceuticals (STU:1T3) has a ROCE % of -31.18% as of Mar. 2026.
Is Syndax Pharmaceuticals' ROCE % too high?
Syndax Pharmaceuticals' current ROCE % is -31.18%. Overall, Syndax Pharmaceuticals has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' ROCE % compare to IOVA and GLUE?
Syndax Pharmaceuticals' ROCE % of -31.18% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Syndax Pharmaceuticals's current ROCE % is -31.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Syndax Pharmaceuticals (STU:1T3) is currently considered Possible Value Trap. The stock's GF Value™ is €698.80, compared to a current price of €19.84 — trading 97.2% below its estimated fair value. The current ROCE % is -31.18%. Syndax Pharmaceuticals' overall GF Score™ is 34/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Syndax Pharmaceuticals (STU:1T3), the current ROCE % is -31.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syndax Pharmaceuticals (STU:1T3) Overvalued in 2026?

Based on GuruFocus' analysis, Syndax Pharmaceuticals stock appears to be undervalued. The current stock price of €19.84 is trading 97.2% below its estimated GF Value™ of €698.80. GuruFocus considers Syndax Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1T3:

  • ROCE %: -31.18%
  • GF Value™: €698.80 vs. price of €19.84 (97.2% below fair value)
  • GF Score™: 34/100 with 9 warning signs

No single metric tells the full story. See the STU:1T3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
34GF Score

Get the complete analysis for STU:1T3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.84
Price
€698.80
GF Value